Viracor's inSIGHT T Cell Immunity test delivers an understanding of a patient's response to viral antigens providing critical insight to aid in treatment decisions.
The test measures CD4+ and CD8+ T Cell response to the SARS-CoV-2 spike (S) and nucleocapsid (N) proteins to independently evaluate cell-mediated immunity to Coronavirus SARS-CoV-2 that causes COVID-19.
Utilizing flow cytometry and intracellular cytokine staining, SARS-CoV-2 inSIGHT testing could be an important tool for evaluating immunological memory to the SARS-CoV-2 virus, and even indicate a level of protection from further infection.
SARS-CoV-2 inSIGHT testing joins a robust menu of COVID-19 testing, including the recently-launched cPASS Coronavirus SARS-CoV-2 Neutralizing Antibody test.
When used in combination with the Neutralizing Antibody test, results from the tests could help physicians evaluate two areas of our adaptive immune system that can indicate immunity.
When neutralizing antibody response begins to diminish months after exposure to the virus or vaccine, the presence of T cell immunity may signify long-term immunity.
A specialist in infectious disease testing for over 35 years, Viracor has launched molecular and serological tests to aid in the evaluation of naturally infected or vaccinated individuals.
Furthermore, Viracor's SARS-CoV-2 RT-PCR assay offers the best sensitivity of the 117 laboratories that have submitted results to FDA's SARS-CoV-2 Reference Panel, with a limit of detection of 180 NAAT Detectable Units/mL.
Eurofins Viracor has over 30 years of diagnostic expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients.
Eurofins Viracor is a subsidiary of Eurofins Scientific (EUFI.PA), a leader in bio-analytical testing, and one of the world leaders in genomic services.
Eurofins is Testing for Life. With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins' companies offer a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary